Mario Strazzabosco’s Post

A recent Yale study has identified a connection between the gut microbiome and the development of liver disease in cystic fibrosis patients. About 30% of patients with cystic fibrosis report liver abnormalities and 10% of these patients go on to experience severe liver disease. Traditionally, cystic fibrosis-related liver disease was thought to be caused primarily by defective bile secretion due to the dysfunctional CFTR protein, which limited treatment options. Roughly 100 trillion microorganisms form the human gut microbiome, aiding in digestion, immunity, metabolism, and other bodily processes. Researchers have previously found that disturbances to this microbiome contribute to the development of many diseases. This study, led by Romina Fiorotto, PhD, and Mario Strazzabosco, MD, PhD, analyzed the gut and liver in preclinical cystic fibrosis models. Significantly, these models showed harmful gut microbiota, increased intestinal permeability, and inflammation. The researchers found that these intestinal changes were pivotal for developing cystic fibrosis-related liver disease. Notably, the study demonstrated that restoring intestinal CFTR function or using antibiotics to correct imbalances in microorganisms can help reduce liver inflammation. More in the story by Jordan Shaked. https://lnkd.in/eS8AFtwq

We are grateful to the Strazzabosco family for sponsoring the ISSNAF YI Franco Strazzabosco Award in memory of their father. Mario Strazzabosco shares with us the original idea behind this award.

We are thrilled to announce the release of our article, "Hepatitis B and C in Europe: an update from the Global Burden of Disease Study 2019" on the Lancet Public Health. Our GBD report provides detailed figures and maps of the burden of HBV-related and HCV-related liver disease and its evolution during the second decade of the 21st century. These figures are an invaluable resource for policy makers and other stakeholders in their efforts to bring about real change and to convince payers to move forward to achieve viral hepatitis elimination goals as early as possible, at the level of each European country. Whether elimination happens in 2030 or a few years later in some countries does not really matter, as long as it happens within a reasonable timeframe. The time to act is now. Download the article here: https://lnkd.in/dAcnaCTN #HBV #HCV #GBD